Submitted:
23 January 2025
Posted:
27 January 2025
You are already at the latest version
Abstract
Modern therapeutics have come to focus attention on liposomal drug delivery systems as innovative and effective vehicles for targeted drug delivery. Lipid-based vesicles may encapsulate drugs that are either hydrophilic or hydrophobic, bringing about unique advantages such as improved bioavailability, protection of the encapsulated drug from degradation, and the potential to provide controlled and sustained release. Liposomal systems have also been formulated to produce different kinds of formulations including surface-modified liposomes, stealth liposomes, and cationic liposomes; each has a different therapeutic application. The introduction of liposomal systems into some newly emerging technologies like nanotechnology helps target drugs better and personalize treatment protocols. This review on the basics in drug delivery as liposomes that covers structural and compositional aspects, mechanisms associated with the encapsulation, and release, also incorporates new developments in the formulations of liposomal, comparisons between liposomes, and other types of delivery systems, and possibilities in the integration of herbal medicines, such as the Tribulus terrestris to enhance therapeutic performance. Further discussed issues are scaling up, stability, and regulatory challenges of liposomal formulation, besides the opportunities for further advancements of liposomal technology in future pharmaceutical applications. Thus, it is expected that the role of liposomes in personalized medicine will continue to increase significantly with a good prospect for the creation of safer, more efficient, and targeted therapies for most diseases.
Keywords:
- Overview and significance of liposomal systems
- Historical evolution and the rationale for developing liposomal carriers
- Introduction to nanoparticles in drug delivery and their comparison with liposomes
- Phospholipid bilayer: Components and properties
- Key types of liposomes (Conventional, stealth, and cationic liposomes)
- Techniques for drug loading in liposomes
- Controlled release mechanisms and influencing factors
- Development of surface-modified liposomes (ligands, PEGylation)
- Personalized care with nanotechnology-based targeting strategies
- Formulation of mouth-dissolving films for liposomal drug delivery
- Chewable and effervescent tablet integration for liposomal systems
- Nanoparticles vs. liposomal systems: A comparative analysis
- Alternative vesicular systems: Proniosomes and effervescent tablets
- Advances in herbal treatments and liposome compatibility (focus on Tribulus terrestris)
- Applications of herbal medicines with liposomal formulations for targeted delivery
- Scalability, stability, and regulatory challenges
- Opportunities for advancing liposomal technology
1. Introduction to Liposomal Drug Delivery Systems
1.1. Historical Evolution and Rationale for Developing Liposomal Carriers
1.2. Introduction to Nanoparticles in Drug Delivery and Their Comparison with Liposomes
| No. | Nomenclature | Description |
| 1 | Nanoparticles | Emerging drug delivery systems that provide better precision in drug delivery. Nanoparticles include solid lipid nanoparticles (SLNs), polymeric nanoparticles, and liposomes. |
| 2 | Liposomes | A unique type of nanoparticle with a lipid bilayer capable of encapsulating both hydrophobic and hydrophilic drugs, mimicking biological membranes. |
| 3 | Comparison of Nanoparticles and Liposomes | While both operate at nanoscale dimensions for better circulation and tissue penetration, liposomes uniquely encapsulate drugs using a phospholipid bilayer, offering better tissue-specific drug release and interaction with cell membranes. |
| 4 | Modifiable Surface Properties | Liposomes' surface properties can be altered for higher specificity to target particular cell types, a feature not commonly shared by other nanoparticles. |
| 5 | Biocompatibility and Stability | Liposomes offer higher biocompatibility and stability compared to some formulations, making them reliable for long-term therapeutics. |
| 6 | Delivery of Biologically Active Molecules | Liposomes are better suited for delivering proteins, peptides, and nucleic acids. Their protective lipid bilayer prevents enzyme degradation and maintains prolonged drug release, enhancing therapeutic efficacy. |
| 7 | Multifaceted Benefits | Liposomes are versatile due to their size, biocompatibility, and capability to encapsulate a wide variety of drugs. They have become a critical tool in modern drug delivery research. |
2. Structure and Composition of Liposomes
2.1. Phospholipid Bilayer: Components and Properties
2.2. Key Types of Liposomes
2.2.1. Conventional Liposomes
2.2.2. Stealth Liposomes (PEGylated Liposomes)
2.2.3. Cationic Liposomes
3. Mechanisms of Drug Encapsulation and Release
3.1. Techniques for Drug Loading in Liposomes
3.1.1. Passive Loading (Thin-Film Hydration Method)
3.1.2. Active Loading (Ion-Gradient Method)
3.1.3. Reverse-Phase Evaporation Method (REV)
3.1.4. Freeze-Thaw Method
| No. | Nomenclature | Description | Citations |
| 1 | Passive Loading (Thin-Film Hydration Method) | A common and cost-effective technique involving the dissolution of lipids in organic solvents, which are then evaporated to form a thin lipid film. The aqueous drug solution hydrates the film, encapsulating hydrophilic drugs in the aqueous core and hydrophobic drugs in the lipid bilayer. | [11] |
| 2 | Active Loading (Ion-Gradient Method) | A method using ion gradients (e.g., ammonium sulfate) to drive drugs into liposomes. Particularly effective for weakly acidic or basic drugs, this technique offers higher encapsulation efficiency and controlled drug loading compared to passive methods. | [11,12] |
| 3 | Reverse-Phase Evaporation Method (REV) | The drug is dissolved in an organic solvent and forms a reverse-phase system with lipids. After reducing the solvent under pressure, this method achieves high encapsulation efficiency for hydrophilic and hydrophobic drugs, especially high-molecular-weight compounds. | [11] |
| 4 | Freeze-Thaw Method | Involves repeated cycles of freezing and thawing in the presence of a drug solution and lipids. This method creates multilamellar vesicles and is commonly used for large-scale production due to its ability to entrap larger amounts of drugs than other methods. | [11] |
3.2. Controlled Release Mechanisms and Influencing Factors
3.2.1. Diffusion-Controlled Release
3.2.2. pH-Sensitive Release
3.2.3. Thermo-Sensitive Release
3.2.4. Enzyme-Mediated Release
3.2.5. Electrostatic and Surface Modifications
4. Innovations in Liposomal Formulations
4.1. Development of Surface-Modified Liposomes (Ligands, PEGylation)
4.1.1. PEGylation
4.1.2. Targeting Ligands
4.2. Personalized Care with Nanotechnology-Based Targeting Strategies
4.3. Formulation of Mouth-Dissolving Films for Liposomal Drug Delivery
| No. | Nomenclature | Description |
| 1 | Mouth-Dissolving Films (MDFs) | Innovative oral drug delivery systems that dissolve quickly in the mouth, replacing tablets and capsules. Advantages include fast onset of action, ease of administration, and improved patient compliance, especially for dysphagia patients. |
| 2 | Incorporation of Liposomes into MDFs | Liposomes encapsulate poorly soluble or bioavailable drugs to enhance their absorption through the oral mucosa, bypassing the gastrointestinal tract and avoiding drug degradation in the acidic gastric environment. |
| 3 | Advantages of Liposomal MDFs | Improved bioavailability, protection from gastric degradation, and efficient delivery of active drugs directly to the target site. |
| 4 | Applications of Liposomal MDFs | Useful for a broad spectrum of drugs, including pain relievers, antihypertensive medications, and antidepressants. |
4.4. Chewable and Effervescent Tablet Integration for Liposomal Systems
5. Comparative Analysis with Other Drug Delivery Systems
5.1. Nanoparticles vs. Liposomal Systems: A Comparative Analysis
| No. | Nomenclature | Description |
| 1 | Nanoparticles | Composed of polymers, metals, or lipids; size ranges from 1 to 100 nm. Surface properties can be engineered to improve drug targeting, offering enhanced stability, cell penetration, and delivery of hydrophilic and hydrophobic drugs. |
| 2 | Liposomal Systems | Consist of a bilayer phospholipid membrane that encapsulates both hydrophilic and hydrophobic drugs. Liposomes are biocompatible, biodegradable, and provide controlled and sustained drug release, making them excellent for long-term use. |
| 3 | Drug Loading and Delivery | Nanoparticles are highly versatile and can carry a wide variety of drugs for both passive and active targeting. Liposomes, while versatile, excel in encapsulation flexibility, drug protection, and controlled release. |
| 4 | Targeting Ability and Barrier Crossing | Nanoparticles, due to their smaller size, can easily cross biological barriers like the blood-brain barrier, allowing more accurate tissue targeting. Liposomes are more suited for controlled release and general biocompatibility. |
| 5 | Application Decision | The choice between nanoparticles and liposomes depends on the drug, disease, required drug profile, and delivery approach. Both have specific advantages tailored to different medical needs. |
5.2. Alternative Vesicular Systems: Proniosomes and Effervescent Tablets
6. Herbal Approaches and Liposomal Integration
6.1. Advances in Herbal Treatments and Liposome Compatibility (Focus on Tribulus terrestris)
6.2. Applications of Herbal Medicines with Liposomal Formulations for Targeted Delivery
7. Challenges and Opportunities
7.1. Scalability, Stability, and Regulatory Challenges
7.2. Opportunities for Advancing Liposomal Technology
8. Conclusion:
References
- Sengar, A. (2023). Targeting methods: A short review including rationale, goal, causes, strategies for targeting. International Journal of Research Publication and Reviews, 4(8), 1379–1384. ISSN 2582-7421.
- Jagrati, K. M., & Sengar, A. (2024). Liposomal vesicular delivery system: An innovative nano carrier. World Journal of Pharmaceutical Research, 13(13), 1155–1169. [CrossRef]
- 3. Prajapati, R. N., Jagrati, K., Sengar, A., & Prajapati, S. K. (2024). Nanoparticles: Pioneering the future of drug delivery and beyond. World Journal of Pharmaceutical Research, 13(13), 1243–1262.
- Sengar, A., Jagrati, K., & Khatri, S. (2024). Enhancing therapeutics: A comprehensive review on naso-pulmonary drug delivery systems for respiratory health management. World Journal of Pharmaceutical Research, 13(13), 1112–1140.
- Sengar, A., Vashisth, H., Chatekar, V. K., Gupta, B., Thange, A. R., & Jillella, M. S. R. S. N. (2024). From concept to consumption: A comprehensive review of chewable tablets. World Journal of Pharmaceutical Research, 13(16), 176–189.
- Sengar, A., Yadav, S., & Niranjan, S. K. (2024). Formulation and evaluation of mouth-dissolving films of propranolol hydrochloride. World Journal of Pharmaceutical Research, 13(16), 850–861.
- Sengar, A., Tile, S. A., Sen, A., Malunjkar, S. P., Bhagat, D. T., & Thete, A. K. (2024). Effervescent tablets explored: Dosage form benefits, formulation strategies, and methodological insights. World Journal of Pharmaceutical Research, 13(18), 1424–1435.
- Sengar, A., Saha, S., Sharma, L., Hemlata, Saindane, P. S., & Sagar, S. D. (2024). Fundamentals of proniosomes: Structure & composition, and core principles. World Journal of Pharmaceutical Research, 13(21), 1063–1071.
- Sengar, A. (2024). Precision in Practice: Nanotechnology and Targeted Therapies for Personalized Care. Preprints. [CrossRef]
- Sengar, A. (2024). Precision in practice: Nanotechnology and targeted therapies for personalized care. International Journal of Advanced Nano Computing and Analytics, 3(2), 56–67.
- Sengar, A. (2025). Innovations and Mechanisms in Liposomal Drug Delivery: A Comprehensive Introduction. Preprints. [CrossRef]
- Sengar, A. (2025). Liposomal Drug Delivery Systems: An Intro as a Primer for Advanced Therapeutics. Preprints. [CrossRef]
- Sengar, A. (2025). Targeting Strategies in Liposomal Drug Delivery. Preprints. [CrossRef]
- 14. Sengar, A., Chatekar, V. K., Andhare, S. B., & Sharma, L. (2025). Clinical pharmacology of antibiotics: Mechanisms, therapeutic uses, and resistance patterns. World Journal of Pharmaceutical Research, 14(1), 1531–1545. [CrossRef]
- Sengar, A., et al. (2025). Advancing urolithiasis treatment through herbal medicine: A focus on Tribulus terrestris fruits. World Journal of Pharmaceutical Research, 14(2), 91–105.
- Sengar, A. (2024). Liposomes and beyond: Pioneering vesicular systems for drug delivery. Preprints. https://www.preprints.org/manuscript/202412.2230/v1.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).